Expression and Clinical Significance of CD147 in Genitourinary Carcinomas

Han, Zhengxue; He, Hui‐Chan; Bi, Xiangjun; Qin, Weijun; Dai, Qi-Shan; Zou, Jun; Ye, Yongkang; Liang, Yu‐Xiang; Zeng, Guohua; Zhu, Gang; Chen, Zhi‐Nan; Zhong, Weide

doi:10.1016/j.jss.2008.11.838

Cited by 40 publications

(58 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pT3/pT4 tumours, the median overall survival time was 14.7 months, which was reduced to 9.2 months if the tumours were CD147 positive. In accordance with our results, several authors have found that CD147 overexpression seems to be correlated with a worse outcome and a cisplatin-resistant profile [12][13][14].…”

Section: Discussionsupporting

confidence: 93%

“…Additionally, we decided to include CD147 immunoexpression in the model, due to its known biological relevance as a prognostic factor probably associated with chemotherapy resistance [12][13][14], and to the significant influence of the expression of this parameter in the OS of patients with pT3/pT4 tumours included in our series. For statistical analysis, we considered two groups: group 1 (low aggressiveness profile), in which cases with none, one or two of the above mentioned parameters were present; group 2 (high aggressiveness profile), which included cases with three to five positive parameters.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

“…CD147 seems to be related with cisplatin resistance of bladder cancer [12]. Overexpression of CD147 in patients with bladder cancer associates with poor prognosis [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

Afonso

Longatto‐Filho

Baltazar

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Background Urothelial bladder carcinoma (UBC) is a chemo-sensitive tumour, but the response to treatment is heterogeneous. CD147 has been associated with chemotherapy resistance. We aimed to define tumours with an aggressive phenotype by the combined analysis of clinicopathological and biological parameters.Methods 77 patients with T1G3 or muscle-invasive UBC treated by radical cystectomy were studied. Immunohistochemistry was performed to detect CD147, heparanase, CD31 (blood vessels identification) and D2-40 (lymphatic vessels identification) expressions. The immunohistochemical reactions were correlated with the clinicopathological and the outcome parameters. 5-year disease free survival (DFS) and overall survival (OS) rates were estimated using the Kaplan-Meier method. Multivariate analysis was performed by Cox proportional hazards analysis. ResultsThe 5-year DFS and OS rates were significantly influenced by the classical clinicopathological parameters, and by the occurrence of lymphovascular invasion.CD147 and heparanase immunoexpression did not affect patients' outcome. However, patients with pT3/pT4 tumours had a median OS time of 14.7 months (95% CI 7.1-22.3, p=0.003), which was reduced to 9.2 months (95% CI 1.5-17.0, p=0.008) if the tumours were CD147 positive. We developed a model of tumour aggressiveness using parameters as stage, grade, lymphovascular invasion and CD147 immunoexpression, which separated a low aggressiveness from a high aggressiveness group, remaining as an independent prognostic factor of DFS (HR 3.746; p=0.019) and OS (HR 3.247; 95% CI 1.015-10.388, p=0.047).Conclusion CD147 overexpression, included in a model of UBC aggressiveness, may help surgeons to identify patients who could benefit from a personalized therapeutic regimen. Additional validation is needed.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

Afonso

Longatto‐Filho

Baltazar

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Diagnosis and treatment of PCa has had many advances in the past 20 years; unfortunately, the existing treatment approaches and surgical interventions have been proven to be inadequate for the management of this disease (1,2). PCa deaths are a result of metastatic disease and treatment of such metastatic disease is one of the major therapeutic challenges.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Proliferation, Invasion, and Migration of Prostate Cancer Cells by Downregulating Elongation Factor-1α Expression

Zhu

Yan

et al. 2009

Mol Med

Self Cite

View full text Add to dashboard Cite

Overexpression of elongation factor-1α (EF-1α) has been reported to contribute to the development and progression of various cancers. However, its role in prostate cancer (PCa) still remains poorly understood. In the present study, we investigate the influence of EF-1α in Du145, a high-grade metastatic PCa cell line, and demonstrate that EF-1α plays an essential role in cellular properties associated with tumor progression, namely cell proliferation, invasion, and migration. In this study, EF-1α expression in human PCa cell line Du145 was reduced by RNA interference (RNAi) technology, and the proliferation, invasion, and migration of EF-1α-reduced Du145 cells were examined. We also detected an EF-1α expression pattern in 20 pairs of primary PCa samples and their corresponding normal tissues. Expression of EF-1α was detectable in four PCa cell lines (22RV1, LnCap, Du145, and PC3), indicating its possible role in pathogenesis of PCa. RNAi-mediated knockdown of EF-1α expression in Du145 cells, which expressed the highest level of EF-1α among four PCa cell lines, led to a decrease in proliferation. Similarly, suppression of EF-1α inhibited Du145 cell migration and invasion through a basement membrane substitute. Furthermore, we found that the normal prostate tissues showed a relatively low level of EF-1α expression, whereas PCa tissues demonstrated significantly higher expression levels of EF-1α (P < 0.001). Taken together, these findings support the hypothesis that EF-1α affects multiple processes involved in tumor progression, and identify EF-1α as a potential therapeutic target.

show abstract

“…Furthermore, treatment with anti-EMMPRIN/CD147 antibody delays the formation of tumors in animal models (38). In addition, treatment with EMMPRIN/CD147-specific RNA interference inhibits the tumorigenicity and metastasis of human lymphoid neoplasms, oral squamous carcinoma, prostate carcinoma and bladder carcinoma cells, increasing their sensitivity to chemotherapeutic drugs (8,39,40). These findings have indicated that RMMPRIN/CD147 may be an important molecule in tumor progression and an attractive target for antitumor treatment.…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Lü

Kim

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Recent studies have shown that extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) promotes adhesion, invasion and metastasis of malignant tumor cells. The aim of this study was to investigate the impact of EMMPRIN/CD147 expression on prognosis and its correlation with clinicopathological characteristics in patients with osteosarcoma. The expression of EMMPRIN/CD147 in 55 surgical specimens from patients with osteosarcoma at stage IIA or above, 15 non-tumor rib bone tissues, three human osteosarcoma cell lines (Saos-2, U-2OS and MG-63), the human osteoblast cell line HOB and the malignant melanoma cell line A375 were examined by immunohistochemistry, western blot analysis and ELISA, respectively. The potential association of the levels of EMMPRIN/CD147 expression in osteosarcoma specimens with the overall survival of patients was statistically analyzed. We found that the EMMPRIN/CD147 was expressed in 45 out of 55 osteosarcomas, with immunoreactivity primarily within the membrane and cytoplasm of tumor cells, but not in the non-tumor bone tissues. We also observed that EMMPRIN/CD147 was expressed in Saos-2, U-2OS, MG-63 and A375, but not in HOB cells. The levels of EMMPRIN/CD147 expression correlated positively with the pathological degree of osteosarcoma and negatively with the survival period of patients with osteosarcoma. The expression of EMMPRIN/CD147 is a potential factor in the development and prognosis of osteosarcoma and may be a novel therapeutic target of human osteosarcoma.

show abstract

Expression and Clinical Significance of CD147 in Genitourinary Carcinomas

Cited by 40 publications

References 24 publications

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

Inhibition of Proliferation, Invasion, and Migration of Prostate Cancer Cells by Downregulating Elongation Factor-1α Expression

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Contact Info

Product

Resources

About